Chronic tearing induced by apremilast.
作者信息
Norris Matthew R, Bielory Leonard
机构信息
Department of Medicine Overlook Medical Center Summit, New Jersey.
Rutgers University Center for Environmental Prediction New Brunswick, New Jersey.
出版信息
Ann Allergy Asthma Immunol. 2018 Sep;121(3):375. doi: 10.1016/j.anai.2018.06.027. Epub 2018 Jun 30.
PMID:29969663
Abstract
摘要
相似文献
1
Chronic tearing induced by apremilast.阿普斯特诱发的慢性流泪。
Ann Allergy Asthma Immunol. 2018 Sep;121(3):375. doi: 10.1016/j.anai.2018.06.027. Epub 2018 Jun 30.
2
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.评估在2019冠状病毒病大流行期间使用阿普米拉斯治疗银屑病的风险。
J Drugs Dermatol. 2021 May 1;20(5):582-583. doi: 10.36849/JDD.5730.
3
Apremilast for the management of moderate to severe plaque psoriasis.阿普米拉斯用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2017 Apr;10(4):349-360. doi: 10.1080/17512433.2017.1293519. Epub 2017 Feb 17.
4
Apremilast in the treatment of psoriasis and psoriatic arthritis.阿普司特治疗银屑病和银屑病关节炎。
Skin Therapy Lett. 2015 Sep-Oct;20(5):1-6.
5
Safety evaluation of apremilast for the treatment of psoriasis.阿普米司特治疗银屑病的安全性评估。
Expert Opin Drug Saf. 2017 Mar;16(3):381-385. doi: 10.1080/14740338.2017.1288714. Epub 2017 Feb 7.
6
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.阿普米司特治疗中重度斑块状银屑病的药效学评估。
Expert Opin Drug Metab Toxicol. 2016 Sep;12(9):1121-8. doi: 10.1080/17425255.2016.1206886. Epub 2016 Jul 14.
7
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.在 LIBERATE 研究中，接受阿普司特治疗或从依那西普治疗转换的中重度斑块状银屑病患者中，阿普司特治疗 104 周的安全性和疗效。
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.
8
Real-world use of apremilast for patients with psoriasis in Japan.日本银屑病患者阿普米司特的真实世界应用。
J Dermatol. 2018 Nov;45(11):1345-1348. doi: 10.1111/1346-8138.14617. Epub 2018 Aug 31.
9
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.阿普司特治疗顽固性斑块状银屑病的疗效、耐受性及药效学：一项II期开放标签研究。
J Drugs Dermatol. 2013 Aug;12(8):888-97.
10
A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.磷酸二酯酶抑制作用及磷酸二酯酶4抑制剂在临床皮肤科潜在作用的综述。
Dermatol Online J. 2014 May 16;20(5):22608.
引用本文的文献
1
Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast.喉假瘤：阿普斯特一种此前未报道的副作用
Case Rep Dermatol. 2020 Dec 16;12(3):275-281. doi: 10.1159/000511697. eCollection 2020 Sep-Dec.
2
Off-label studies on apremilast in dermatology: a review.阿普斯特在皮肤科的超适应证研究：综述。
J Dermatolog Treat. 2020 Mar;31(2):131-140. doi: 10.1080/09546634.2019.1589641. Epub 2019 Apr 2.
3
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.阿普司特治疗银屑病及其他疾病：对一种小分子药物寄予厚望
Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18.
Zotero 插件